Skip to content
Screener

Pre-Tax Income at other companies

Insulet logo
InsuletPODD
$118.7M+318%
Medtronic logo
MedtronicMDT
$1.83B+45.4%
Embecta Corp. logo
Embecta Corp.EMBC
$27.6M-61.8%
AdaptHealth logo
AdaptHealthAHCO
-$20.11M-284%
InfuSystem Holdings logo
InfuSystem HoldingsINFU
$1.42M+460%
Abbott logo
AbbottABT
$1.52B-29.1%

Other financials

Income statement

See full
Revenue$254.6M+5.8%
Gross profit$144.8M+15.0%
Operating income-$13.8M+73.4%
Net income-$21.2M+59.6%
EPS (diluted)-$0.31+60.3%

Balance sheet

See full
Cash & equivalents$62.8M-2.0%
Total debt$739.3M+64.6%
Total equity$130.4M-2.2%
Total assets$1.2B+31.8%

Cash flow

See full
Operating cash flow-$34.6M-265%
CapEx$4.1M-34.7%
Free cash flow-$38.7M-146%

Valuation

See full
Market cap$1.56B+128%
Enterprise value$2.23B+109%
P/S1.5×+0.8×

Profitability

See full
Gross margin56%+3.5pp
Operating margin-4.4%-1.9pp
Net margin-6.1%-2.5pp
FCF margin-0.8%-0.4pp

Returns & leverage

See full
Return on equity-48%-17.5pp
Debt / equity5.7×+2.3×
Current ratio3.2×+0.7×

Where this comes from

Reported directly by Tandem Diabetes Care in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Tandem Diabetes Care’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001438133-26-000125
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Interest expense(2,450)(1,905)(4,654)(3,767)
Loss from equity method investment(5,641)(3,375)(9,506)(6,917)
Total other income (expense), net(6,866)(5,912)(9,309)(7,123)
Loss before income taxes(20,658)(57,722)(40,535)(179,811)
Income tax expense (benefit)510(5,322)1,0263,145
Net loss$(21,168)$(52,400)$(41,561)$(182,956)
Other comprehensive income (loss):
Unrealized gain (loss) on short-term investments$(692)$(98)$(1,719)$325

Item 1. Financial Statements.

FAQ

What is Tandem Diabetes Care's pre-tax income?
Tandem Diabetes Care (TNDM) reported pre-tax income of -$20.66M in Q2 2026.
How has Tandem Diabetes Care's pre-tax income changed year-over-year?
Tandem Diabetes Care's pre-tax income increased by 64.2% year-over-year, from -$57.72M to -$20.66M.
What is the long-term trend for Tandem Diabetes Care's pre-tax income?
Over 4 years (2021 to 2025), Tandem Diabetes Care's pre-tax income has grown at a 89.5% compound annual growth rate (CAGR), from $15.9M to -$204.95M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Tandem Diabetes Care's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude